ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS
Ngày 10/09/2021 09:30 | Lượt xem: 629

Findings of the STOPDAPT-2 ACS trial presented during a hot line session at the European Society of Cardiology’s 2021 congress (ESC 2021, 27–30 August, virtual), do not support the use of one month of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients undergoing stent implantation.

The STOPDAPT-2 trial previously demonstrated that among patients undergoing percutaneous coronary intervention (PCI), one month of DAPT followed by clopidogrel monotherapy resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, compared with 12 months of DAPT with aspirin and clopidogrel. In that trial, 62% of patients had stable coronary artery disease and 38% had ACS.

To generate sufficient statistical power to compare the effect of the two treatments in ACS patients alone, the STOPDAPT-2 ACS trial enrolled 2,988 ACS patients and pooled the results with the 1,148 ACS patients in STOPDAPT-2—for a total of 4,136 patients. Both trials used the same protocol. Participants were randomly assigned in a 1:1 ratio to one-month DAPT followed by clopidogrel monotherapy or 12-month DAPT after PCI with cobalt-chromium everolimus-eluting stents.

The primary outcome was a composite of cardiovascular and bleeding outcomes at one year: death from cardiovascular causes, myocardial infarction, definite stent thrombosis, ischaemic or haemorrhagic stroke, and Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding.

The two major secondary endpoints were: a cardiovascular composite outcome (death from cardiovascular causes, myocardial infarction, definite stent thrombosis, ischaemic or haemorrhagic stroke); and TIMI major or minor bleeding.

The primary outcome occurred in 65 patients (3.2% one-year cumulative incidence) assigned to one-month DAPT and 58 patients (2.83%) assigned to 12-month DAPT (hazard ratio [HR] 1.14; 95% confidence interval [CI] 0.80–1.62; p=0.06 for noninferiority).

The major secondary cardiovascular outcome occurred in 56 (2.76%) patients in the one-month DAPT group and 38 (1.86%) patients in the 12-month DAPT group (HR 1.50; 95% CI 0.99–2.26). The major secondary bleeding outcome occurred in 11 (0.54%) patients allocated to one-month DAPT and 24 (1.17%) patients allocated to 12-month DAPT (HR 0.46; 95% CI 0.23-0.94).

Study author Hirotoshi Watanabe of Kyoto University, Kyoto, Japan, said: “One-month DAPT and subsequent clopidogrel monotherapy failed to achieve non-inferiority for net clinical benefit compared with standard 12-month DAPT after ACS. There was a trend toward an increase in cardiovascular events despite a reduction in major bleeding events.”

Source CardiovascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua google bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua twitter bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua MySpace bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua LinkedIn bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua stumbleupon bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua icio bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua digg bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua yahoo bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua yahoo bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua yahoo bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS Chia sẽ qua yahoo bài: ESC 2021: STOPDAPT-2 ACS does not support clopidogrel monotherapy one-month after ACS

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP